This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by MAXWELL, M. H. Articles by KLEEMAN, C. R. Search for Related Content PubMed Articles by MAXWELL, M. H. Articles by KLEEMAN, C. R.

(Circulation. 1962;26:1279.)
© 1962 American Heart Association, Inc.

---

Hemodynamic Studies of a Monoamine Oxidase Inhibitor, DL-Serine-N²-Isopropylhydrazide (RO 4-1038)

Mechanism of Hypotensive Action

M. H. MAXWELL M.D.¹; H. C. GONICK M.D.¹; L. SCADUTO M.D.¹; M. L. PEARCE M.D.¹; C. R. KLEEMAN M.D.¹

¹ From the Department of Medicine, University of California Medical Center, and Wadsworth Hospital, Veterans Administration Center, Los Angeles, California.

Hemodynamic studies were performed on 11 patients with severe diastolic hypertension before and after the chronic administration of the monoamine oxidase inhibitor, RO 4-1038.

Although postural hypotension was more marked, the blood pressure decreased significantly in the supine position as well. The hypotensive effect was attributable almost solely to decreased total peripheral resistance and was unrelated to changes in cardiac output, blood volume, or sodium space. Renal plasma flow and glomerular filtration rate were unchanged.

Evidence is presented which suggests that the decrease in blood pressure was not caused by adrenergic blockade.

If RO 4-1038 is a representative monoamine oxidase inhibitor then its hemodynamic action is unique among the clinically useful hypotensive drugs.